147 related articles for article (PubMed ID: 14717958)
1. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.
Exaire JE; Lincoff AM
J Thromb Haemost; 2004 Jan; 2(1):7-9. PubMed ID: 14717958
[No Abstract] [Full Text] [Related]
2. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? No.
Ragosta M; Sarembock IJ
J Thromb Haemost; 2004 Jan; 2(1):10-2. PubMed ID: 14717959
[No Abstract] [Full Text] [Related]
3. Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice.
Young JJ; Kereiakes DJ
J Interv Cardiol; 2002 Apr; 15(2):115-20. PubMed ID: 12063806
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes.
Boersma E
J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743
[No Abstract] [Full Text] [Related]
5. Routine use of abciximab in coronary stenting?
Stables RH
Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267
[No Abstract] [Full Text] [Related]
6. Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention?
Cole JH; Weintraub WS
Circulation; 2003 Dec; 108(23):2831-3. PubMed ID: 14662689
[No Abstract] [Full Text] [Related]
7. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty.
Khan SS; Forrester J
N Engl J Med; 1997 Oct; 337(17):1243; author reply 1244-5. PubMed ID: 9340527
[No Abstract] [Full Text] [Related]
8. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
Cho L; Topol EJ; Balog C; Foody JM; Booth JE; Cabot C; Kleiman NS; Tcheng JE; Califf R; Lincoff AM
J Am Coll Cardiol; 2000 Aug; 36(2):381-6. PubMed ID: 10933346
[TBL] [Abstract][Full Text] [Related]
9. Economic issues in glycoprotein IIb/IIIa receptor therapy.
Hillegass WB; Newman AR; Raco DL
Am Heart J; 1999 Jul; 138(1 Pt 2):S24-32. PubMed ID: 10385788
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
[TBL] [Abstract][Full Text] [Related]
11. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
[TBL] [Abstract][Full Text] [Related]
12. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy.
Schrogie JJ
Am Heart J; 1999 May; 137(5):S126-8. PubMed ID: 10220614
[No Abstract] [Full Text] [Related]
13. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
Topol EJ; Mark DB; Lincoff AM; Cohen E; Burton J; Kleiman N; Talley D; Sapp S; Booth J; Cabot CF; Anderson KM; Califf RM
Lancet; 1999 Dec; 354(9195):2019-24. PubMed ID: 10636365
[TBL] [Abstract][Full Text] [Related]
14. Economics of coronary stenting and GPIIb/IIIa blockade.
Weintraub WS
Eur Heart J; 2001 Aug; 22(16):1366-8. PubMed ID: 11482914
[No Abstract] [Full Text] [Related]
15. Readministration of abciximab in percutaneous coronary intervention.
Fry ET
J Invasive Cardiol; 1999 Apr; 11(4):251-8. PubMed ID: 10745525
[TBL] [Abstract][Full Text] [Related]
16. Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction.
Cannon CP
Clin Cardiol; 1999 Aug; 22(8 Suppl):IV30-6. PubMed ID: 10492851
[TBL] [Abstract][Full Text] [Related]
17. Massive pulmonary hemorrhage in a patient treated with a platelet glycoprotein IIb/IIIa inhibitor.
Sitges M; Villa FP
Int J Cardiol; 1997 Dec; 62(3):269-71. PubMed ID: 9476687
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
19. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators
N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
[TBL] [Abstract][Full Text] [Related]
20. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials.
van de Werf F
Eur Heart J; 1996 Mar; 17(3):325-6. PubMed ID: 8737200
[No Abstract] [Full Text] [Related]
[Next] [New Search]
